摘要
目的:探讨冠心病(CHD)患者治疗前后血清IL-2、SOD和血浆ET-1水平的变化和意义。方法:应用放射免疫分析对65例CHD患者进行了血清IL-2、SOD和血浆ET-1检测(其中稳定型心绞痛30例,不稳定型心绞痛22例,急性心肌梗死13例,并以35名正常健康人作比较。结果:CHD患者在治疗前血清IL-2、SOD水平非常显著地低于正常人组(P<0.01),而血浆ET-1水平又非常显著地高于正常人组(P<0.01)。经中西医结合治疗3个月后与正常人组比较无显著性差异(P>0.05)。结论:血清IL-2、SOD和血浆ET-1水平的变化参与了CHD的发生与发展。
Objective To study the changes of serum IL-2,SOD and plasma ET-1 levels after treatment in patients with coronary heart diseases.Methods Serum IL-2,SOD and plasma ET-1 levels were detected with RIA in 65 patients with coronary heart diseases（30SAP,22UAP,13AMI）and 35 controls.Results Before treatment,serum IL-2,SOD levels in CHD patients were significantly lower than those in controls（P0.01）,while the plasma ET-1 levels in CHD patients were significantly higher than those in controls（P0.01）.After treatment for 3 months,those variables were about the same as in controls（P0.05）.Conclusion The serum IL-2,SOD and plasma ET-1 levels were well correlated to the development of CHD.
出处
《放射免疫学杂志》
CAS
2010年第3期263-264,共2页
Journal of Radioimmanology
关键词
冠心病
白细胞介素-2
稳定型心绞痛
不稳定型心绞痛
急性心肌梗死
超氧化物岐化酶
内皮素-1
coronary heart diseases（CHD）
interleukin-2（IL-2）
stable angina pectoris（SAP）
unstable angina pectoris（UAP）
acute myocardial infaretion（AMI）
superoxide dismutase（SOD）
endothelin-1（ET-1）
